Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Cancer Res. 2016 Nov 21;77(3):632–645. doi: 10.1158/0008-5472.CAN-15-2556

Figure 1. Knockout of SULF2 inhibits HCC progression.

Figure 1

A. Representative images of livers from Sulf2 WT, Sulf2 Hz KO and Sulf2 Hm KO mice, carrying tumors after DEN-treatment. At 14 days of age mice received a single intraperitoneal injection of DEN. All mice were sacrificed at 8 months old and their liver and lungs were examined for tumors. B. Hematoxylin-eosin (H&E) staining of representative tumors from Sulf2 WT, Sulf2 Hz KO and Sulf2 Hm KO mice showed typical HCC. C. Bar graphs showed that significantly smaller proportions of Sulf2 Hm KO and Sulf2 Hz KO mice presented ≥5 tumors/mouse (top panel) and tumor volume ≥35 mm3 (lower panel) compared with Sulf2 WT mice. D. Bar graph representing lung metastasis incidence (left panel) and H&E staining (right panel) showed that Sulf2 WT mice developed lung metastasis but Sulf2 Hm KO did not. *P< .05; **P< .01.